Finerenone (Kerendia) prevents cardiovascular (CV) and some renal events in type 2 diabetes patients with earlier stages of kidney disease, the FIGARO-DKD trial showed. In the trial's stage 1 to 4 ...
A new analysis of the EMPEROR-Preserved trial sheds light on the efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results